Blue light flexible cystoscopy with hexaminolevulinate in non-muscle-invasive bladder cancer: review of the clinical evidence and consensus statement on optimal use in the USA — update 2018

Blue light cystoscopy (BLC) with hexaminolevulinate (HAL) during transurethral resection of bladder cancer improves detection of non-muscle-invasive bladder cancer (NMIBC) and reduces recurrence rates. Flexible BLC was approved by the FDA in 2018 for use in the surveillance setting and was demonstra...

Descripción completa

Detalles Bibliográficos
Autores principales: Lotan, Yair, Bivalacqua, Trinity J., Downs, Tracy, Huang, William, Jones, Jeffrey, Kamat, Ashish M., Konety, Badrinath, Malmström, Per-Uno, McKiernan, James, O’Donnell, Michael, Patel, Sanjay, Pohar, Kamal, Resnick, Matthew, Sankin, Alexander, Smith, Angela, Steinberg, Gary, Trabulsi, Edouard, Woods, Michael, Daneshmand, Siamak
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2019
Materias:
Consensus Statement
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7136177/
https://www.ncbi.nlm.nih.gov/pubmed/31019310
http://dx.doi.org/10.1038/s41585-019-0184-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7136177/
https://www.ncbi.nlm.nih.gov/pubmed/31019310
http://dx.doi.org/10.1038/s41585-019-0184-4

Ejemplares similares